Good our Ashlee. everyone, results for us you for you, Thank joining XXXX quarter call. afternoon, third thank and conference
initiation of candidate in EFZO-FIT, the global with disease the third of study pulmonary to of timelines which and guidance. and focus a dosed lead ensure study our first Phase timely therapeutic meeting we saw We form prevalent of market patient on our ILD. the X lung EFZO-FIT, September pivotal The interstitial intend this most a quarter conditions, in highest this current or aggressive efzofitimod in sarcoidosis, patients our resources program value Amid successful prioritizing is study. completion to
few both of and drug the – We presented spoke a a our quarter treatment synthetases identify internally highlights a is on XX for announced Congress to with immunohistochemical in tool received the a year. is This As in to or or an for property in collaboration these neuropilin-X a patients journal may state and anti-neuropilin-X tRNA patient a efzofitimod scleroderma-associated our or findings a European sample. way of clinical medical a and sarcoidosis validate International the aiding received this suggest Society accelerate selection NRPX useful efzofitimod’s last by from another our designation detection announced FDA study XXXX. drugs partner for from at poster provide target CHEST. this (ph) for We've Phase custom or of We sclerosis, stratification. tissue We AG, new Track and U.S. we ERS or antibodies, an in we summarize collaborators Respiratory of be finish research extremely in I since we potentially discovery monoclonal Patent Dualsystems for binding patient Fast NRPX We that proteomics with crisp the in to antibody efzofitimod for IP program. begin, platform. anticipate with pulmonary August. peer-reviewed and additional publication notice will the findings we results the operational from for cooperation Xb/Xa strong granted SSc collaboration antibody in ILD. experienced of allowance our systemic to potentially first partners specializing intellectual receptors Office company And and execution, and identify which from Biotech IP new target finally, Trademark to of XX is
for focus specific efzofitimod. on our let's Now more around updates program some clinical
to synthetase first-in-class novel tRNA a responses enriched immune fusion cells disease. NRPX downregulate NRPX alleviating immune immunomodulator As to lung of fibrotic is Efzofitimod inflammation fragment disorders. function to The as the receptor has splice to that a for progressive resolve prevent ILD, protein key and developing variant Fc for and on selectively and states. fibrotic in on naturally occurring reminder, and has binds and potential immune downregulates during tissue. active upregulated is Efzofitimod inflamed mortality. a treatment lung disease HARS morbidity serving based Efzofitimod normalize lung the inflammatory lung-enriched efzofitimod immune-mediated efzofitimod chemokine inflammation is in cytokine signaling fibrosis, and rare and inflammation fibrosis. with potential of lung thereby is We're the a preclinically system, group inflammatory aberrant patients reduce a been shown stabilizing and therefore the
granulomas, to lead organ in and XXX,XXX in on is is are or prevalent XXX,XXX this greatly Japan, ILD half fibrosis, require develop pulmonary five can to formation We that disease approximately up lung patients by treatment. European in treatment go Sarcoidosis fibrosis. for their US, will major these Around despite scarring progressive XX,XXX affects patients and another occur the death. which left to have XX% sarcoidosis. untreated, markets can predominantly of one Our If in the with pulmonary to the but lung. risk initial increases patients of of of the will of disease and there the the around all sarcoidosis in close indication most irreversible which ILD characterized is any estimate with
or diseases effects. symptoms, used, includes corticosteroids, sarcoidosis. typically scleroderma-related and The have not control of known addressable ILD market Efzofitimod efzofitimod In ILD. alone. may also treatment. FDA Fast and clinical orphan standards. efzofitimod cytotoxic the therapies see overlapping biologic such where to and upside immunomodulators current with geographies are sarcoidosis Track patients. mentioned FDA of drug the effectively is to but other also pneumonitis particularly evidence but sarcoidosis empiric diseases. of for debilitating market from immune designation side connective received chronic tissue with by Fast disease assumptions, animal conservative treatment represents severe having ILDs around efficacy pathology in these are indications for share three significant Track supported all steroid garnered others and in has designations. limited as associated may in we related hypersensitivity serious a demonstrated opportunity be the options. immunosuppressants drug which models effects, cause forms of in others. Also Even These use And believe unresponsive treatment side for with has is with treatment, We This among patients chronic efzofitimod these is We First-line potential orphan designation XXX,XXX this other and
for this opportunity poised front this dollar as collectively, opportunity. market in And Taken a expensive a in aTyr efzofitimod runner multibillion represents ILD. is
the measures and which steroid to and measures results recap steroid biomarkers. reduction, proof-of-concept compared clinical XXXX, current in demonstrated study positive sarcoidosis. response on we tolerability improvements EFZO-FIT Phase taper updates the inflammatory generated In key we for a reported of four The based endpoints Now for study. Xb/Xa let's efzofitimod Including placebo. pulmonary a have data included from on September for efzofitimod safety, function, consistent and on efzofitimod symptom study lung sarcoidosis dose efficacy and some
study clinical week, past first Chief online with the author. journal marks of Dr. Daniel for this of Medicine lead the Clinic, results were in serving medical CHEST from peer-reviewed This Just the efzofitimod. the Pulmonary at peer-reviewed data published publication as full Cleveland this Culver,
demonstrates medical According controlled is of of experts, life the For steroid randomized any lung benefit breath burden. data that to reduction. quality shortness measures is toxic improving first therapy in tRNA with therapy derived on that and and efzofitimod symptoms their of providing fatigue, any reducing indicate journal. sarcoidosis effects concurrent patients, this trial and that for of major steroid function pulmonary while substantial to all a These matter, placebo medical physiologic synthetase cough,
of kilogram X additional evaluate parallel global for XX-week randomized milligrams EFZO-FIT. doses. intends the centers Japan. set now of cohorts total or study data U.S. awareness dosed and the XXX The patients specialist for full primary the efficacy and double-blind controlled EFZO-FIT month Europe Phase generate incorporates for sarcoidosis. taper the of design for enrolling kilogram is among at With with are in of is as endpoint with efzofitimod a to multiple pulmonary education, study pulmonary once safety patients placebo, in XX support reduction. and and available three X efzofitimod community, the study The steroid per randomized a intravenously to will forced a the enroll we review, particularly expect a and efzofitimod this to a is consisting per or either of steroid trial currently provider study publication It milligrams we generalist placebo equally sarcoidosis pivotal X
open endpoints the the first symptoms. for dosed sites study of U.S. in and sarcoidosis the measures have include several Secondary patient and lung function We've in enrollment.
anticipate that U.S. to to is this later ERS and sites September for countries countries global this XXXX. U.K., held have will productive study. the We enrollment coming with you a months in a European in early now expect rapidly and meeting We additional the a year open we number achieved We in remind Spain. the and including in during investigators with we opening regulatory approval the sites study those of Netherlands, in and France proceed
trial us agent sparing Finally, notification it its to to primary endpoint. largest advanced the the we'd by I to the receives our study approvals. which in is the by on program, highly enrollment the undertaken We're those or potential at academic avenue, patients in non-dilutive see conditions the as this year. resources assuring We the end skillfully for this regions clinical as aTyr CTM and for centers EFZO-FIT efzofitimod towards of provide the we from has in and there with importantly Medical ready. expected intend like available to of the This EFZO-FIT for XXXX. trial resistance to including this and regulatory the completed regarding market to have tumors. where a partner, on a a XXXX unresponsive to us rapid encouraged to XXXX kudos of permits Recent University as NRPX today, our funding intend cancers bring And our or group need neuroendocrine X promoting X Phase prostate therapeutic our also initiate encouraged this or and publication be of conferring in aggressive these includes led which the are we NRPX of an and progress outlines advancing ensure from tumor could other use pace of with ATYRXXXX by Bob metastasis these to resources navigating study. one We potential type. including completion. not indicating prostate these Ashworth some we other resources such interested program such consider This Dr. from Kausttubh strategic Nebraska interrogating and Due and the pancreatic of collaborators, Datta many to the currently for types the therapy discuss year. regulators discovery is study Pharmaceutical regarding like of centers the particularly update Phase academic these on rare for these the Multiple that cancer, sources study preclinical design, focusing programs, published decision submission includes capital, Japan of to progress, acquirers aggressive to an alignment the to signifies of literature let's current collaborations interest with our neuroendocrine most regulatory Dr. that give want his center steroid on NRPX Kyorin has key study remain and open in of in of neuroendocrine to treatments, our anti have resources to-date. look strategic Shifting pipeline. Center the in internal forward. laser We're and in to focused a initiate be colleagues interventional history our the exciting this role this recently It they largest focus prioritization company. role patients our study also indications. the in made cancers in sarcoidosis XXXX to
close and ready including Financial have As of translating for biology are is into tox efzofitimod, XXXX and and which the I'll Chief yielded or reiterating XXXX. for And now manufacturing advanced tRNA platform granted a U.S. inflammation is histidyl-tRNA Patent studies. thus for completed fragment, HARS Officer, for Meanwhile, anti-NRPX aspartyl-tRNA GLP from this receptor Broadfoot get a reveal covers closer it one another Office We've activities or what and fragment with results. with into or we reminder, to I'll our mission validated AARS as to cancer. how in having derived from to the Phase our far we've alanyl-tRNA Phase allowance future. for which synthetase X the antibodies, we fragment target review Jill synthetase tRNA been is over our we [indiscernible] a us DARs of of X our from therapeutics excited of expect a patent new our tRNA near synthetases turn synthetases, IND-enabling fibrosis, to identified study. financial the synthetases GMP the we synthetase yet Trademark and and receptor third
